NeuroPace (NPCE) Cash from Operations Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 21.54% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 13.50% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 14.62% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 124.64% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -11.16% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 78.72% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -0.23% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | -12.60% |
| 10 | NeuroPace | 470.13 Mn | 418.43 Mn | 18.91 Mn | -85.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.86% |
| Mar 31, 2026 | 21.33% |
| Dec 31, 2025 | 110.64% |
| Sep 30, 2025 | -9.03% |
| Jun 30, 2025 | 47.35% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | -42.42% |
| Sep 30, 2024 | 22.96% |
| Jun 30, 2024 | 10.77% |
| Mar 31, 2024 | 22.66% |
| Dec 31, 2023 | 58.09% |
| Sep 30, 2023 | 66.79% |
| Jun 30, 2023 | 58.86% |
| Mar 31, 2023 | 14.93% |
| Dec 31, 2022 | 4.01% |
| Sep 30, 2022 | -56.56% |
| Jun 30, 2022 | -76.86% |
| Mar 31, 2022 | -93.22% |
| Dec 31, 2021 | -27.99% |
| Sep 30, 2021 | 18.07% |